Based on the in vitro testing results, we then created 5 PDO-specific virtual patients by introducing inter-individual variation within certain physiological parameters (tumor growth rate, degree of MET amplification, and drug potency) and calibrating model simulation results against the respective in vitro dose-response datasets (Figures 8A,B; Supplementary Figures S6A–E, S7A–E, S8A–E). This evidence concerns the gene MET and neoplasm.